93 Sacituzumab govitecan in uterine and ovarian carcinosarcomas

Volume: 29
Published: Sep 1, 2019
Abstract
Objectives null Carcinosarcomas (CS) are highly aggressive gynecologic malignancies containing both carcinomatous and sarcomatous elements. Sacituzumab govitecan (SG) is a novel antibody-drug conjugate (ADC) targeting trophoblast antigen 2 (Trop-2), a cell surface glycoprotein highly expressed in many epithelial tumors, to deliver SN-38, the active metabolite of irinotecan. This study aimed to evaluate the efficacy of SG in primary CS cell lines...
Paper Details
Title
93 Sacituzumab govitecan in uterine and ovarian carcinosarcomas
Published Date
Sep 1, 2019
Journal
Volume
29
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.